TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01456468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral all-trans retinoic acid (ATRA)
Description: The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process.
Study: NCT02634229

Intervention type: GENETIC
Intervention: blood sample

Intervention type: GENETIC
Intervention: blood sample
Study: NCT01458652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin
Description: Kremezin is an oral adsorbent, 9g/day in treatment arm
Study: NCT00987220

Intervention type: DRUG
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Intervention: donepezil (Aricept)
Description: 5mg oral
Study: NCT01479673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry measurement of Resting Energy Expenditure .
Description: Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
Study: NCT01785550

Intervention type: OTHER
Intervention: Ultrasound of nerve and muscle
Description: Ultrasound of 6 muscles and 2 nerves will be performed.
Study: NCT00878774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: ToleroMune Ragweed dose 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: ToleroMune Ragweed dose 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: ToleroMune Ragweed dose 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: ToleroMune Ragweed dose 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: ToleroMune Ragweed dose 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 2 weeks apart
Study: NCT01993654

Intervention type: PROCEDURE
Intervention: HRT III with Non-Contact Cornea Rostock Module
Description: Confocal imaging of the conjunctival lesion

Intervention type: PROCEDURE
Intervention: HRT III with Non-Contact Cornea Rostock Module
Description: Confocal imaging of the conjunctival lesion
Study: NCT02903966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
Study: NCT02996240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 FFA
Description: Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
Study: NCT01993654

Intervention type: PROCEDURE
Intervention: HRT III with Non-Contact Cornea Rostock Module
Description: Confocal imaging of the conjunctival lesion

Intervention type: PROCEDURE
Intervention: HRT III with Non-Contact Cornea Rostock Module
Description: Confocal imaging of the conjunctival lesion

Intervention type: PROCEDURE
Intervention: HRT III with Non-Contact Cornea Rostock Module
Description: Confocal imaging of the conjunctival lesion
Study: NCT01929278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT Gel (clindamycin 1% and tretinoin 0.025%)
Description: Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel patch
Description: Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blank patch
Description: Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
Study: NCT00822991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CE-US (Sonazoid™)
Description: screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-mode US
Description: screening by conventional B-mode US every 3-5 months
Study: NCT01113983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation via transapical and transfemoral approach
Study: NCT03684395

Intervention type: DRUG
Intervention: DOACs: Rivaroxaban, Dabigatran, Apixaban
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection

Intervention type: DRUG
Intervention: Standard of care (Warfarin)
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Study: NCT02397278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma (PRP)
Description: Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
Study: NCT00844389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near to infrared light retinal stimulation
Description: Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Green light stimulation
Description: Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
Study: NCT03444961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAREN system training
Description: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
Study: NCT00664872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proactive psychosocial intervention by care managers
Description: A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
Study: NCT02224105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone low
Study: NCT00664872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: case management
Study: NCT04540601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)
Description: We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday.
Study: NCT03547180

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Capnometry-Assisted Respiratory Training
Description: The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
Study: NCT01646151

Intervention type: DRUG
Intervention: Bimatoprost
Description: Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
Study: NCT03547180

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-vivo exposure
Description: In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
Study: NCT03254004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
Study: NCT03185767

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood sampling
Study: NCT02224105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone high

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
Study: NCT00409799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-0401 (a new bone graft substitute)
Description: 1 time application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-0401 (a new bone graft substitute)
Description: 1 time application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I-0401 (a new bone graft substitute)
Description: 1 time application
Study: NCT03682250

Intervention type: DEVICE
Intervention: FreeStyle Libre Pro
Description: A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
Study: NCT01786278

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic stenting
Description: Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
Study: NCT03682250

Intervention type: DEVICE
Intervention: Holter monitor
Description: A Holter monitor will be used to measure heart's activity
Study: NCT02209246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Pain Interference
Study: NCT02894788

Intervention type: OTHER
Intervention: ICU admission
Study: NCT02209246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Pain Interference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Pain Behavior

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Pain Behavior

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Physical Function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Physical Function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MISS-21

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MISS-21
Study: NCT01431430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100 000 UI
Description: Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 12 000 UI
Description: Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
Study: NCT02189434

Intervention type: OTHER
Intervention: Serum procalcitonin lab draws
Description: Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients.
Study: NCT01089335

Intervention type: PROCEDURE
Intervention: Histological investigation of the SN
Description: 99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.

Intervention type: PROCEDURE
Intervention: Histological investigation of the SN
Description: 99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
Study: NCT00494949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: 200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
Study: NCT00930306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: 12 doses, Given as capsule, 2 mg \& 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 2 doses, Given as Tablet, 2x50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: 2 doses, Given as Tablet, half of 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Tablet, 20 mg
Description: 2 doses, Given as Tablet, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Tablet, 7.5 mg
Description: 2 doses, Given as Tablet, 7.5 mg
Study: NCT00293397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads loaded with doxorubicin hydrochloride
Description: Doxorubicin eluting beads
Study: NCT02311452

Intervention type: DEVICE
Intervention: Peripherally Inserted Central Catheter (PICC)
Description: Post-discharge antibiotics delivered via a PICC line.
Study: NCT02429089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients.
Study: NCT02471586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by IVUS
Description: Imaging type
Study: NCT03515733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, identical appearance to experimental tablet
Study: NCT00413127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: administration of lidocaine intravenously or epidural or administration of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: administration of lidocaine intravenously or epidural or administration of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: administration of lidocaine intravenously or epidural or administration of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: administration of lidocaine intravenously or epidural or administration of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Administration of placebo i.v.
Study: NCT00729495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: dose form
Study: NCT04143321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
Study: NCT00729495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: dose form
Study: NCT02471586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by OCT
Description: Imaging type

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by Angiography
Description: Imaging type
Study: NCT02996110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified Dose on Specified Days